Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 4:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 708 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Recurrent Astrocytoma, Grade IV Clear all
Completed Phase 2 Interventional Results available

Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma

NCT03463265
View directory record Official record
Conditions
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
Interventions
nab-sirolimus, nab-sirolimus + temozolomide, nab-sirolimus + bevacizumab, nab-sirolimus + lomustine, nab-sirolimus + marizomib (MRZ), nab-sirolimus + temozolomide + radiotherapy
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Fullerton, California • Newport Beach, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 7, 2026, 4:42 AM EDT
Recruiting Phase 1Phase 2 Interventional

Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma

NCT04977375
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Pembrolizumab, Stereotactic Radiation Therapy, Surgical Resection
Drug · Radiation · Procedure
Lead sponsor
Chirag G. Patil
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 7, 2026, 4:42 AM EDT
Completed Phase 1 Interventional

CC-5013 in Treating Patients With Recurrent Glioma

NCT00036894
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
lenalidomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 7, 2026, 4:42 AM EDT
Completed Phase 2 Interventional Results available

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

NCT02844439
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma, Brain Tumor
Interventions
Tesevatinib
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
Tucson, Arizona • Duarte, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 7, 2026, 4:42 AM EDT
Terminated Phase 1 Interventional

Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma

NCT01499251
View directory record Official record
Conditions
Glioblastoma
Interventions
Phase 1 Dose Escalation, Phase 1b, Ancillary Study
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Oct 7, 2026, 4:42 AM EDT
Completed Phase 1 Interventional Results available

Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas

NCT02015819
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor, Anaplastic Oligoastrocytoma
Interventions
E. coli CD-expressing genetically modified neural stem cells, flucytosine, leucovorin calcium, pharmacological study, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Oct 7, 2026, 4:42 AM EDT
Recruiting Phase 1 Interventional

Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM

NCT04991870
View directory record Official record
Conditions
Recurrent Gliosarcoma, Recurrent Supratentorial Glioblastoma, Supratentorial Gliosarcoma
Interventions
Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Resection
Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 7, 2026, 4:42 AM EDT
Recruiting Not applicable Interventional

Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma

NCT06090903
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma, Resectable Glioblastoma
Interventions
Biospecimen Collection, Magnetic Resonance Imaging, Medical Chart Review
Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 7, 2026, 4:42 AM EDT
Completed Phase 1Phase 2 Interventional

ATN-161 and Carboplatin in Treating Patients With Recurrent Malignant Glioma

NCT00352313
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
ATN-161, carboplatin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2012 · Synced Oct 7, 2026, 4:42 AM EDT
Completed Phase 1 Interventional

Feasibility of Individualized Therapy for Recurrent Glioblastoma

NCT03681028
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
Individualized therapy
Drug
Lead sponsor
Jennifer Clarke
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 7, 2026, 4:42 AM EDT
Recruiting Phase 1 Interventional

First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma

NCT07560865
View directory record Official record
Conditions
Astrocytoma, Glioblastoma, Progressive Disease
Interventions
FT536, Biopsy/ Intratumoral Injection/ Gross Tumor Resection, Blood/ Cerebrospinal Fluid/ Tumor Pathology
Biological · Procedure · Diagnostic Test
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 7, 2026, 4:42 AM EDT
Terminated Phase 3 Interventional

VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM

NCT03149575
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioblastoma, Glioma, GBM, Brain Cancer
Interventions
VAL-083, Dianhydrogalactitol, Physician's Choice of Salvage Therapy - temozolomide, Physician's Choice of Salvage Therapy - lomustine, Physician's Choice of Salvage Therapy - carboplatin
Drug
Lead sponsor
DelMar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 7, 2026, 4:42 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of BGJ398 in Patients With Recurrent GBM

NCT01975701
View directory record Official record
Conditions
Recurrent Glioblastoma or Other Glioma Subtypes
Interventions
BGJ398
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Oct 7, 2026, 4:42 AM EDT
Completed Phase 3 Interventional

SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme

NCT00003293
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
leflunomide, procarbazine hydrochloride
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2012 · Synced Oct 7, 2026, 4:42 AM EDT
Withdrawn Phase 2 Interventional

Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma

NCT03014804
View directory record Official record
Conditions
Giant Cell Glioblastoma, Gliosarcoma, Oligodendroglioma, Recurrent Glioblastoma, Small Cell Glioblastoma
Interventions
autologous dendritic cells pulsed with tumor lysate antigen Vaccine, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
Biological · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 7, 2026, 4:42 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

NCT05664243
View directory record Official record
Conditions
Glioblastoma
Interventions
Autologous genetically modified gamma-delta T cells, Allogeneic genetically modified gamma-delta T cells
Biological
Lead sponsor
In8bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Birmingham, Alabama • Tampa, Florida • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 7, 2026, 4:42 AM EDT
Completed Phase 1 Interventional

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

NCT00387933
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
hydroxyurea, imatinib mesylate, vatalanib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 7, 2026, 4:42 AM EDT
Active, not recruiting Phase 2 Interventional

Surgical Pembro +/- Olaparib w TMZ for rGBM

NCT05463848
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma
Interventions
Pembrolizumab, Olaparib, Temozolomide
Drug
Lead sponsor
L. Nicolas Gonzalez Castro, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 7, 2026, 4:42 AM EDT
Completed Phase 1 Interventional

Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

NCT02709226
View directory record Official record
Conditions
Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme, Gliosarcoma
Interventions
Radiation
Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 7, 2026, 4:42 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

NCT01609790
View directory record Official record
Conditions
Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Oligodendroglioma, Recurrent Brain Neoplasm, Recurrent Glioblastoma
Interventions
Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study, Placebo Administration, Trebananib
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
243
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 172 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 7, 2026, 4:42 AM EDT
Completed Phase 1 Interventional

Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors

NCT02644291
View directory record Official record
Conditions
Medulloblastoma, Astrocytoma, Grade III, Glioblastoma, Anaplastic Astrocytoma, Brain Stem Neoplasms, Malignant, Oligodendroblastoma, Anaplastic Oligodendroglioma, Malignant Glioma
Interventions
Mebendazole
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
1 Year to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
St. Petersburg, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Oct 7, 2026, 4:42 AM EDT
Active, not recruiting Phase 1 Interventional

Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma

NCT03389230
View directory record Official record
Conditions
Glioblastoma, Malignant Glioma, Recurrent Glioma, Refractory Glioma, WHO Grade III Glioma
Interventions
HER2(EQ)BBζ/CD19t+ T cells, Laboratory Biomarker Analysis, Leukapheresis
Biological · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 7, 2026, 4:42 AM EDT
Completed Phase 2 Interventional Results available

AMG 102 and Avastin for Recurrent Malignant Glioma

NCT01113398
View directory record Official record
Conditions
Glioblastoma Multiforme, Gliosarcoma
Interventions
AMG 102, Avastin
Drug
Lead sponsor
Katy Peters
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Oct 7, 2026, 4:42 AM EDT
Not listed Early Phase 1 Interventional

FDG and FDOPA PET Demonstration of Functional Brain Abnormalities

NCT04315584
View directory record Official record
Conditions
Glioblastoma
Interventions
Positron Emission Tomography, Computed Tomography, Multiparametric Magnetic Resonance Imaging Scan, Fludeoxyglucose F-18, fluorine F 18 fluorodopa
Procedure · Radiation
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 7, 2026, 4:42 AM EDT